Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy.

Hirofumi KomakiYoshihiro MaegakiTsuyoshi MatsumuraKazuhiro ShiraishiHiroyuki AwanoAkinori NakamuraSatoru KinoshitaKatsuhisa OgataKeiko IshigakiShinji SaitohMichinori FunatoSatoshi KuruTakahiro NakayamaYasuyuki IwataHiroyuki YajimaShin'ichi Takeda

Published in: Annals of clinical and translational neurology (2020)

The HPGDS inhibitor TAS-205 showed a favorable safety profile in DMD patients. Further research is required to examine the effectiveness of TAS-205 in a larger trial.

Keyphrases

duchenne muscular dystrophy
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
systematic review
prognostic factors
muscular dystrophy
peritoneal dialysis